Search Results
Aug 17, 2026, 09:05 ET Mathnasium and Baked by Melissa Team Up for Back-to-School Season: A Nationwide Thank You to Teachers
Mathnasium Method™ — the result of decades of hands-on instruction and development — has been transforming the lives of children in grades PK-12 by offering comprehensive assessments, fully individualized learning plans, and teaching true math comprehension. With more than 1,300 learning centers
More news about: Mathnasium
Aug 17, 2026, 08:00 ET OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
ONC-783-001ONC-783-001 is a Phase 1 open-label, dose-escalation study in the United States (U.S.) to evaluate the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic
More news about: OncoC4
Aug 13, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
action]On July 21, 2026, Agios issued a press release "announc[ing] topline results from the Phase 2 trial of tebapivat, an oral pyruvate kinase (PK) activator, in patients aged 16 years or older with sickle cell disease. "The press release disclosed that "[t]he trial did not demonstrate the level
More news about: Pomerantz LLP
Aug 13, 2026, 07:00 ET Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating a favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The Company has received the IND
More news about: Accro Bioscience Inc.
Aug 13, 2026, 00:02 ET PointsKash Announces Expanded Up to $100 Million Strategic Capital Commitment from Hawk Capital
approximately 2,100 company-owned KashPoint financial services kiosks, support technology and platform integrations, expand merchant activation, advance PK Pay, strengthen working capital and operating reserves, and prepare the infrastructure required for broader national deployment.The second phase
More news about: PointsKash Inc.
Aug 11, 2026, 14:56 ET Investment Watches Ranks No. 9 on 2026 Inc. 5000, Named Austin's Fastest-Growing Private Company
https://drive.google.com/drive/folders/1mGyZ218-Ec-FeJN-_pk3O9AxBgupH7uz?usp=sharing
More news about: Investment Watches
Aug 11, 2026, 10:30 ET Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
on August 7, 2026.FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).GV101 is a best-in-class selective ROCK2 inhibitor that increases frataxin
More news about: Graviton Bioscience Corporation
Aug 06, 2026, 23:02 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
action]On July 21, 2026, Agios issued a press release "announc[ing] topline results from the Phase 2 trial of tebapivat, an oral pyruvate kinase (PK) activator, in patients aged 16 years or older with sickle cell disease." The press release disclosed that "[t]he trial did not demonstrate the level
More news about: Pomerantz LLP
Aug 06, 2026, 07:30 ET Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of repeated intrathecal injections of RAG-17 in patients with SOD1 mutations. The participating sites
More news about: Ractigen Therapeutics
Aug 04, 2026, 10:00 ET Q2BI Expands Asia-Pacific Footprint with New Offices in Taipei, Kuala Lumpur, and Melbourne
in 2009, Q2BI has grown into an organization of more than 300 professionals across clinical data management, biostatistics, statistical programming, PK/PD, medical writing, medical monitoring and review, safety surveillance, regulatory support, data science, and software engineering. This multidisciplinary
More news about: Q-Square Business Intelligence (Q2BI)
Aug 04, 2026, 00:00 ET PointsKash Begins Phase One of National KashPoint™ Infrastructure Rollout with Acquisition of More Than 2,100 Cryptocurrency Kiosks
fintech ecosystem, including PK Pay™, PointsKash's next-generation mobile financial application currently anticipated to receive app store approval for public launch at the beginning of Q4 2026.Together, the KashPoint™ kiosk network and PK Pay™ mobile platform will form the cornerstone
More news about: PointsKash Inc.
Jul 31, 2026, 08:00 ET Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure
forward and prepare for our 5th IND filing, these proceeds are instrumental across the development and ultimately the supply of our targeted and PK-optimized radiopharmaceuticals.""Ratio is a leader in radiopharmaceutical innovation and it has backed up science with execution — hitting clinical
More news about: Ratio Therapeutics Inc.
Jul 31, 2026, 04:51 ET 快手科技將於2026年8月19日公佈2026年第二季度及中期業績
https://s1.c-conf.com/diamondpass/10055639-hu7y6t.html 英文同聲傳譯專線（僅供聆聽）：https://s1.c-conf.com/diamondpass/10055640-pk81aw.html 參會者預先登記時可選擇中文專線或英文同聲傳譯專線。請注意，英文同聲傳譯專線僅供聆聽。完成登記後，參會者將會收到列有會議撥入詳情、會議密碼及特定登記號碼的電子郵件。參會者可使用相關訊息直接參與電話會議。參會者可在電話會議開始前及進行期間，隨時預先登記。此外，公司投資者關係網站亦會提供電話會議（包括中文專線及英文同聲傳譯專線）的直播及存檔網絡廣播，網址為：
More news about: 快手科技
Jul 31, 2026, 04:50 ET Kuaishou Technology to Report 2026 Second Quarter and Interim Financial Results on August 19, 2026
(listen-only mode):https://s1.c-conf.com/diamondpass/10055640-pk81aw.html Participants can choose between the Chinese and English simultaneous interpretation options for pre-registration above.
More news about: Kuaishou Technology
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
action]On July 21, 2026, Agios issued a press release "announc[ing] topline results from the Phase 2 trial of tebapivat, an oral pyruvate kinase (PK) activator, in patients aged 16 years or older with sickle cell disease." The press release disclosed that "[t]he trial did not demonstrate the level
More news about: Pomerantz LLP
Jul 30, 2026, 09:06 ET HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates
program supports AI drug-discovery teams in translating AI-generated targets, molecules and mechanism hypotheses into in vivo pharmacology, mechanism, PK/PD, biomarker and pre-IND translational evidence in autoimmune and allergy disease models. HKEY-AI2Vivo™ 1.0 at a GlanceWhat it
More news about: HKeyBio
Jul 30, 2026, 01:29 ET Dasher Neuroscience schließt die Patientenrekrutierung für die weltweite klinische Phase-2-Studie mit dem führenden KI-basierten Wirkstoffkandidaten YA-101 gegen Multisystematrophie (MSA) ab
unerwünschter Ereignisse (AEs), um das Sicherheits- und Verträglichkeitsprofil von YA-101 zu bewerten. Zu den sekundären Endpunkten zählen pharmakokinetische (PK) Parameter sowie die klinische Wirksamkeit, die anhand der „Unified Multiple System Atrophy Rating Scale" (UMSARS) und des 10-Meter-Gehtests bewertet
More news about: Dasher Neuroscience Holdings Inc.
Jul 29, 2026, 19:29 ET /C O R R E C T I O N -- InstaMed® Pharmaceuticals/
efficient absorption while bypassing gastrointestinal degradation.The platform was recently validated through a double-blinded pharmacokinetic (PK) study demonstrating faster absorption and more consistent circulating peptide levels using oral dissolvable strip delivery compared to traditional administration
More news about: InstaMed® Pharmaceuticals
Jul 29, 2026, 16:05 ET Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
this year. VK2735 Maintenance Dosing Study Data Expected 3Q26. Based on VK2735's promising efficacy and differentiated pharmacokinetic (PK) profile, the company is evaluating a range of novel dosing regimens for both the induction and the long-term maintenance of weight loss. Providing
More news about: Viking Therapeutics, Inc.
Jul 29, 2026, 07:00 ET CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
controls store-operated calcium entry and lung inflammation via Orai1 regulation. Arterioscler Thromb Vasc Biol. 2024;44:2271-2287.Sutton R, Garg PK, Miller J, et al. Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized, controlled, dose-ranging, phase 2b trial.
More news about: CalciMedica, Inc.
Jul 29, 2026, 05:30 ET Dasher Neuroscience completa el reclutamiento de pacientes en el ensayo clínico global de fase 2
adversos (EA) para evaluar el perfil de seguridad y tolerabilidad de YA-101. Los criterios de valoración secundarios incluyen parámetros farmacocinéticos (PK), así como la eficacia clínica evaluada mediante la Escala Unificada de Calificación de Atrofia Multisistémica (UMSARS) y la prueba de marcha de 10 metros.Designación
More news about: Dasher Neuroscience Holdings Inc.
Jul 29, 2026, 03:01 ET Dasher Neuroscience achève le recrutement des patients dans le cadre de l'essai clinique mondial de phase II portant sur le YA-101, son principal candidat-médicament développé grâce à l'IA, destiné au traitement de l'atrophie multisystématisée (AMS)
afin d'évaluer le profil de sécurité et de tolérance du YA-101. Les critères d'évaluation secondaires comprennent les paramètres pharmacocinétiques (PK), ainsi que l'efficacité clinique évaluée à l'aide de l'échelle Unified Multiple System Atrophy Rating Scale (UMSARS) et du test de marche sur 10 mètres.Désignations
More news about: Dasher Neuroscience Holdings Inc.
Jul 28, 2026, 08:12 ET Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
incidence and severity of Adverse Events (AEs) to assess the safety and tolerability profile of YA-101. Secondary endpoints include pharmacokinetic (PK) parameters, as well as clinical efficacy evaluated via the Unified Multiple System Atrophy Rating Scale (UMSARS) and the 10-Meter Walk Test.U.S.
More news about: Dasher Neuroscience Holdings Inc.
Jul 28, 2026, 08:12 ET Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
incidence and severity of Adverse Events (AEs) to assess the safety and tolerability profile of YA-101. Secondary endpoints include pharmacokinetic (PK) parameters, as well as clinical efficacy evaluated via the Unified Multiple System Atrophy Rating Scale (UMSARS) and the 10-Meter Walk Test.U.S.
More news about: Dasher Neuroscience Holdings Inc.
Jul 28, 2026, 08:00 ET PRM Pharma and Ingenus Pharmaceuticals Announce Orange Book Listing of Patent Protecting HemiClor® Formulation Technology
https://hemiclor.com/wp-content/uploads/2026/03/HEMICLOR-PRESCRIBING-INFORMATION.pdf Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management
More news about: PRM Pharma, LLC